These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27554774)

  • 1. The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.
    Poulsen SH; Urup T; Grunnet K; Christensen IJ; Larsen VA; Jensen ML; Af Rosenschöld PM; Poulsen HS; Law I
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):373-381. PubMed ID: 27554774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
    Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients.
    Munck Af Rosenschold P; Law I; Engelholm S; Engelholm SA; Muhic A; Lundemann MJ; Roed H; Grunnet K; Skovgaard Poulsen H
    Radiother Oncol; 2019 Jan; 130():149-155. PubMed ID: 30446316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
    Suchorska B; Jansen NL; Linn J; Kretzschmar H; Janssen H; Eigenbrod S; Simon M; Pöpperl G; Kreth FW; la Fougere C; Weller M; Tonn JC;
    Neurology; 2015 Feb; 84(7):710-9. PubMed ID: 25609769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[
    Harat M; Małkowski B; Roszkowski K
    Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of
    Moller S; Law I; Munck Af Rosenschold P; Costa J; Poulsen HS; Engelholm SA; Engelholm S
    Radiother Oncol; 2016 Oct; 121(1):132-137. PubMed ID: 27622554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Treatment Response Assessment Using
    Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FET-PET for malignant glioma treatment planning.
    Niyazi M; Geisler J; Siefert A; Schwarz SB; Ganswindt U; Garny S; Schnell O; Suchorska B; Kreth FW; Tonn JC; Bartenstein P; la Fougère C; Belka C
    Radiother Oncol; 2011 Apr; 99(1):44-8. PubMed ID: 21458093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM
    BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
    Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
    Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
    Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
    Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.
    Piroth MD; Galldiks N; Pinkawa M; Holy R; Stoffels G; Ermert J; Mottaghy FM; Shah NJ; Langen KJ; Eble MJ
    Radiat Oncol; 2016 Jun; 11():87. PubMed ID: 27342976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.
    Piroth MD; Pinkawa M; Holy R; Stoffels G; Demirel C; Attieh C; Kaiser HJ; Langen KJ; Eble MJ
    Radiat Oncol; 2009 Nov; 4():57. PubMed ID: 19930657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
    Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ
    Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging.
    Buchmann N; Kläsner B; Gempt J; Bauer JS; Pyka T; Delbridge C; Meyer B; Krause BJ; Ringel F
    World Neurosurg; 2016 May; 89():420-6. PubMed ID: 26893043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.